You are here

Urovant

Urovant's lead drug disappoints in mid-stage study as first big FDA decision looms

Urovant's lead drug disappoints in mid-stage study as first big FDA decision looms

Endpoints

clinical trials

Flag link:

As Urovant gears up for vibegron FDA decision, the biotech gets snapped up by Sumitovant Biopharma

As Urovant gears up for vibegron FDA decision, the biotech gets snapped up by Sumitovant Biopharma

Fierce Biotech

overactive bladder

Flag link:

Vivek Ramaswamy’s Urovant claims a big win in PhIII — but questions linger about a cheap generic and their branded rival

Vivek Ramaswamy’s Urovant claims a big win in PhIII — but questions linger about a cheap generic and their branded rival

Endpoints

Alzheimer's disease

Vivek Ramaswamy

urinary incontinence

Flag link: